Trucheck Diabetes Cancer Screening Test

Truecheck Diabetes is a revolutionary multi cancer screening test, based on a simple blood draw, for early detection of six diabetes related cancers which are more common in diabetic asymptomatic individuals. Trucheck Diabetes is now available in the UK.

Trucheck™ – Diabetes is a non-invasive blood test that is intended to be used for the detection of six types of gastrointestinal cancer or urinary tract cancer in men and women with recently diagnosed or existing Type 2 diabetes such as the Liver cancer, Gallbladder cancer, Pancreatic cancer, Kidney cancer, Bladder cancer and Colon cancer.

Individuals with Type 2 diabetes are twice as likely to be diagnosed with pancreatic or liver cancers as compared to those without Type 2 diabetes. These individuals are also at a higher risk of other cancers such as those of the gallbladder, kidney, bladder and colorectum. These risks have prompted physicians to consider the value of cancer screening for people with diabetes. Studies have shown that early detection of cancer improves survival rates.

Trucheck™ – Diabetes is totally non-invasive, radiation free and can be availed from the comfort of your office or home. Trucheck™ – Diabetes is intended to be performed annually as a routine test.

Many cancers no symptoms until the disease is advanced, and screening may help detect cancer early, when the chances of treatment success are high.

What are the Advantages of Trucheck™ Diabetes Screening Test

Advantages to the individuals:

  1. Wait times for appointments are reduced
  2. Minimized risk of COVID exposure
  3. May be assimilated into annual health check-up
  4. No risk of radiation or those associated with invasive procedures

Advantages to the system:

  1. Reduces risk of COVID transmission and exposure of staff
  2. Reductions in avoidable / non-critical appointments
  3. Minimizes procedures that may be retrospectively deemed unnecessary
  4. Supports decision making in conjunction with existing tests / methods

Why should I consider Trucheck™ Diabetes Screening Test?

Circulating Tumor Cells (CTCs) and their clusters are present in the blood of almost all cancer patients and are undetectable even in seemingly healthy individuals.
Trucheck™ technology to detect and characterise CTCs has been proven through extensive clinical validations involving more than 40,000 participants.The test is a paradigm shift in cancer screening, as it does not involve radiation or invasive procedures. The test is performed at our world-class laboratory, which meets and exceeds all national and international standards.

Trucheck™ Diabetes Screening Test is Accurate

The development of Trucheck™ Diabetic Multicancer Screening Test included extensive Analytical and Clinical validation studies to establish its Accuracy and Reliability.

Advantages of Trucheck™ Diabetes Cancer Screening Test Over Conventional Screening

  • Minimize Procedures – Minimizes procedures that may be retrospectively deemed unnecessary.
  • Radiation Free – No risk of radiation or those associated with invasive procedures.
  • Save Time – Reductions in avoidable / non-critical appointments.
  • Early detection saves lives – late stage survival for most cancers is usually worse than with early stage detection.

Cancer – A Global Perspective

Every year about 18 million women and men are diagnosed with various cancers including carcinomas, sarcomas, neuroendocrine tumors, melanomas. These cancers are also associated with about 9 million deaths. This translates into roughly 34 cancer cases being detected and 18 cancer-related deaths every minute. Annually, these cancers contribute to:

  • ~4.1 million newly diagnosed cases and 1.8 million deaths in Europe (including the UK).
  • ~2.1 million newly diagnosed cases and 550,000 deaths in the US.
  • ~1.2 million newly diagnosed cases and 760,000 deaths in India.

Due to changes in lifestyle as well as other risk factors, these numbers are likely to increase in the future.

FAQs

1. Does Trucheck detect ‘existence of cancer’ or ‘possibility of cancer’? It detects ‘existence of cancer’.

2. Does Trucheck replace conventional cancer screening like mammography?  Trucheck is not intended to be and should not be considered as a replacement for any Standard of Care screening tests.

3. Does a ‘negative’ Trucheck result mean that I am ‘totally’ cancer free? Within the limits of error, a ‘negative’ result is a reasonable indication of undetectable cancer of the type covered by the test. For other cancers not covered by the test, no inference should be drawn from a ‘negative’ result.

4. Does a ‘negative’ Trucheck result mean that I am free from cancer forever? A ‘negative’ results means that at the time of the test there were no detectable cancer cells circulating in the blood.

5. How frequently should Trucheck™ be repeated? As Trucheck™ is a non-invasive blood test, there is no disadvantage in frequent testing. However, we advise that Trucheck™ should be performed every 12 months in case of every negative result.

7. Is Trucheck recommended for a person suspected to have / has symptoms of cancer? No, such individuals should seek expert medical advice without delay.

8. Can Trucheck be used to monitor recurrence after cancer treatment? No.

Trucheck Test Performance

Cancer

Trucheck Sensitivity

Conventional Sensitivity

Trucheck Specificity

Conventional Specificity

Trucheck      PPV

Conventional PPV

Trucheck     NPV

Conventional NPV

Conventional Screening Test

Breast

88.2%

86.9%

99.9%

88.9%

99.9%

69.6%

99.9%

95.9%

Mammogram

Prostate

85.6%

90.0%

99.9%

19.7%

99.9%

33.9%

99.9%

81.0%

PSA

Colon

82.6%

73-98%

99.9%

89%

99.9%

99.9%

Colonoscopy/ CT Colonography

Cancer

85.7%

99.9%

99.9%

99.9%

This table compares the clinical performance of the Trucheck test with conventional cancer screening tests for different cancers. The results are based on a blinded prospective study involving 15,441 cancers, 700 benign cases and 13,919 asymptomatic individuals.

What does the DETECTION RATE mean?

The detection rate or sensitivity is the ability to correctly identify those who DO have cancer in a group of people with and without cancer. For example, in a group of women with and without breast cancer, Trucheck Breast will correctly identify 88.2% of those who DO have breast cancer.

What is SPECIFICITY?

This is the ability to correctly identify those that DO NOT have cancer in a group of people with and without cancer. For example, in a group of women with and without breast cancer, Trucheck Breast will correctly identify 88.2% of those cases who DO NOT have breast cancer.

What is the POSITIVE PREDICTIVE VALUE (PPV)?

This is the likelihood that if the test is positive that the individual WILL actually have cancer. For example, when the Trucheck Breast test shows a high probability of a woman having breast cancer, then there is a 99.9% chance that they WILL actually have breast cancer.

What is the NEGATIVE PREDICTIVE VALUE (NPV)?

This is the likelihood that if the result is negative that the individual WILL NOT have cancer. For example, when the Trucheck Breast test shows a low probability of a woman having breast cancer, then there is a 99.9% chance that they WILL NOT have breast cancer.

Reference

Gaya A. et al. Evaluation of circulating tumor cell clusters for pan-cancer non-invasive diagnostic triaging. (ACS Journal, 2021)
Population – Cancers: 9.416 (Retrospective) & 6.025 (Prospective) • Benign: 700 • Asymptomatic: 13.919 (Prospective)
Parameters – Analyte: C-ETACs, CTCs • Assessment: Colony Detection Assay • Clinical Validation Study
Performance Characteristics – Specificity: 99.3% (Benign) & 100.0% (Asymptomatic) • Sensitivity: 85.2% (Retrospective) & 86.7% (Prospective)